HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
24 hedge funds and large institutions have $16.4M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
47% more capital invested
Capital invested by funds: $11.2M → $16.4M (+$5.26M)
0% more funds holding
Funds holding: 24 → 24 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.71M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$610K |
| 3 |
SC
Samjo Capital
New York
|
+$469K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$399K |
| 5 |
CPA
Cowen Prime Advisors
New York
|
+$209K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$368K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$103K |
| 3 |
Squarepoint
New York
|
-$63.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$59K |
| 5 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$18.6K |
HTGM Hedge Fund Activity: Q2 2021 in Review
24 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q2 2021, worth a combined $16.4M — up 47% from $11.2M a quarter earlier.
Fund positioning in HTGM was balanced in Q2 2021: 3 funds opened new positions, 3 closed out, 10 added to existing stakes and 4 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $1.71M. The largest seller was Renaissance Technologies, cutting an estimated $368K.
- 24 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $16.4M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q2 2021, up 47% quarter-over-quarter.
- 3 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q2 2021 and 3 closed out, a net change of 0 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q2 2021 was AIGH Capital Management, an estimated $1.71M added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q2 2021 was Renaissance Technologies, an estimated $368K sold.
Based on aggregated 13F filings for Q2 2021.